A81988 NEW
| Price | $1970 | $2580 | $3400 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: A81988 | CAS No.: 141887-34-5 |
| Supply Ability: 10g | Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | A81988 |
| Description | A81988 is an antagonist of angiotensin AT1 receptors. |
| In vitro | A81988 (A-81988) is labeled with tritium to a high specific activity of 16 Ci/mmol, and radioligand binding assays on rat liver membranes demonstrate that [3H]A81988 binds with high affinity (KD=0.57 nM), consistent with kinetics assays. Non-specific binding, defined by 1 μM angiotensin-II, is very low (<6% at KD). The binding of [3H]A81988 is competitive and shows appropriate pharmacological specificity for compounds acting at angiotensin AT1 receptors[1]. |
| In vivo | To verify this hypothesis, B2-/- or wild-type mice (B2+/+) are administered a nonpeptide antagonist of Ang II type 1 (AT1) receptors (A81988) from conception through 180 days of age. Untreated B2+/+ and B2-/- served as controls. Blood pressure (BP) and heart rate are monitored with the use of tail-cuff plethysmography at regular intervals. Ventricular weights, diameters, wall thickness, chamber volume, and myocardial fibrosis are measured at 40 and 180 days. No differences are observed in BP, heart rate, and cardiac weight and dimensions between treated and untreated B2+/+. The BP of AT1 antagonist-treated B2-/- is reduced until 70 days; then, it increases to the levels found in untreated B2-/-. AT1 receptor blockade results in a reduction in left ventricular mass, chamber volume, and wall thickness and abrogated myocardial fibrosis in B2-/-[2]. A81988 (A-81988) decreases the BP of Bk2r-/- either in normosodic conditions or after sodium deprivation, whereas in Bk2r+/+ it produces a modest decrease under hyposodic conditions only[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Angiotensin AT1 receptor | A-81988 | A81988 | A 81988 |
| Inhibitors Related | Losartan potassium | Tranilast | Enalapril Maleate | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | Losartan | Ramipril | Diisononyl phthalate | Captopril |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2080404-19-7
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3400.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY